Cutoff: 12 October 2026. Consensus supports discovery and checks of specific source aspects; it is not a primary study, a full-paper audit or a causal probability meter.
Consensus correctly distinguishes estradiol and venlafaxine placebo contrasts from their imprecise direct comparison. Selected original Methods confirm baseline bothersome symptoms, identical pills, randomization and diary-defined primary frequency; Results show both active arms improve that endpoint. The small between-active difference does not prove broad hormone superiority. Original PMID24861828. Access: full_text_partial.
Consensus identifies the right primary symptom and endometrial endpoints. The examined original abstract distinguishes dose-specific frequency and severity success and separates medication-exposed, endometrial-analysis and symptom-substudy populations. Its assertion that the endometrial analysis count simply represents completion is unsupported. The attached correction was identified; no universal zero-risk inference is used. Original PMID29889748. Access: abstract_metadata.
Consensus calls REPLENISH double-dummy blinding maintained. The examined original primary abstract establishes a randomized double-blind single-capsule trial, but does not document allocation-guess performance. A design label cannot verify actual maintained masking, and no invented double-dummy or blinding-integrity check is credited. Original PMID29889748. Access: abstract_metadata.
Consensus appropriately separates symptom benefit from prevention but relies heavily on this later WHI report. Its linked parent has two attached corrections concerning text/supplement and Figure 3. Correction identities were checked, while substantive details remain unavailable in the examined passages, so numerical subgroup claims are withheld. This report remains grouped with the original WHI parents rather than counted as a new independent trial. Original PMID40952729. Access: abstract_metadata.
The observed Consensus search applied a From2014 filter and did not provide the older WHIMS original requested. The independently examined original randomized report shows probable dementia increased with the tested combined regimen among women enrolled aged at least sixty-five. Its age/regimen scope is retained; this is neither proof all modern therapy has the same risk nor evidence of dementia prevention. Provider omission does not erase the original study. Original PMID12771112. Access: abstract_metadata.
Consensus highlights KEEPS symptom relief and discusses transdermal superiority via a network meta-analysis. Selected KEEPS original Methods/Results show both hormone routes reduce symptoms, but cognition does not improve and mood effects differ by route. A network ranking or absent head-to-head superiority result cannot establish that transdermal hormone therapy is universally superior or prevents dementia. Original PMID26035291. Access: full_text_partial.
The requested APHRODITE/INTIMATE distinctions were not substantively supplied in the filtered Consensus response. The examined APHRODITE original supports modest sexual-function benefit in baseline diagnosed HSDD at the tested higher patch dose, alongside dose and safety limits. The indication is not transferred to energy, cognition or muscle in all women. Original PMID18987368. Access: abstract_metadata.
The observed Consensus response does not adjudicate the requested testosterone cognitive originals. Selected original Methods/Results of the dose-response trial document verified hormone exposure and no significant benefit across tested cognitive domains, with small complete-data groups. This bounds broad cognitive claims without declaring every dose/formulation ineffective. Original PMID25430996. Access: full_text_partial.
Independent primary examination preserves the randomized verbal-learning signal that a uniformly negative summary would omit. Other cognitive tasks and general wellbeing did not improve in the same trial. This is a bounded task result with a mapped domain boundary, not evidence of generalized brain protection. Original PMID24716847. Access: abstract_metadata.
The examined dose-response original finds selected muscle-power and lean-mass gains primarily at supraphysiologic exposure, while other physical-function tests did not improve. The same trial also supplies the cognitive and cardiometabolic-marker reports, so these papers are one parent study. A physiological-dose wellbeing claim cannot inherit high-exposure secondary muscle results. Original PMID24281237. Access: full_text_partial.
The provider discusses neurokinin alternatives, but the original OASIS3 Methods/Results verify a prespecified twelve-week primary symptom test and descriptive longer secondary outcomes with more treatment-related adverse events. That design supports a nonhormonal symptom pathway; it does not demonstrate cardiovascular prevention or lifetime safety. Original PMID40920404. Access: full_text_partial.
The automated provider date filter omitted the requested early thermoregulatory original. Its examined primary abstract describes randomized estradiol/placebo treatment with increased sweating threshold and reduced objectively recorded laboratory flushing. This narrows diary-only reporting bias, while its small sample and unisolated complete mediator chain remain limitations. Original PMID11872200. Access: abstract_metadata.
Consensus was used to identify literature and cross-check specific claims about design, endpoints, scope and research gaps. Those aspects were checked against original primary abstracts/status records and selected original Methods/Results passages. Consensus output was not treated as original full text. Provider search omissions are not evidence that a study does not exist. Source access and examination receipts are retained. Scite use or monthly unavailability is recorded per case; provider citation counts do not change causal grades.